Acrivon Therapeutics Inc. (ACRV)

Overview

Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to the development of oncology medicines. Founded in 2018 and headquartered in Watertown, Massachusetts, the company focuses on delivering targeted therapies for cancer patients through precise and innovative methods. Utilizing its proteomics-based patient responder identification platform, Acrivon aims to ensure that each of its oncology medicines reaches the patients most likely to benefit from them. This approach signifies a pivotal move towards personalized medicine in cancer treatment, enabling more effective and tailored therapies that could significantly improve patient outcomes.

Products and Services

List and explanation of Acrivon Therapeutics, Inc.'s products and services:

• ACR-368: This lead clinical candidate embodies Acrivon's commitment to pioneering precise oncology treatments. ACR-368 is a selective small molecule inhibitor targeting CHK1 and CHK2, crucial components in the DNA damage response pathway. It is currently undergoing a Phase II clinical trial to assess its efficacy across various tumor types, including but not limited to platinum-resistant ovarian, endometrial, and bladder cancer. The development of ACR-368 highlights Acrivon's focus on addressing unmet needs in cancer therapy, particularly for patients with these challenging and often treatment-resistant types of cancer.
• Acrivon Predictive Precision Proteomics: This precision medicine platform stands at the core of Acrivon's innovative approach to cancer treatment. By enabling the creation of drug-specific proprietary OncoSignature companion diagnostics, this platform facilitates the identification of patients most likely to benefit from Acrivon’s drug candidates. This not only enhances the potential efficacy of treatments but also streamlines the clinical trial process by targeting those more likely to respond to the therapies under investigation.
• Preclinical Pipeline Programs: Beyond ACR-368, Acrivon is actively developing a range of preclinical stage pipeline programs. These are primarily focused on targeting critical nodes within the DNA damage response (DDR) pathways. The DDR pathways play a pivotal role in cancer cell survival and proliferation, making them an attractive target for the development of new cancer treatments. These preclinical programs underline Acrivon's commitment to expanding its portfolio of innovative oncology therapies and exploring new avenues for cancer treatment.
• ACR-2316: As part of its pursuit of novel cancer therapies, Acrivon is developing ACR-2316, a dual inhibitor targeting WEE1 and PKMYT1. These proteins are key regulators of the cell cycle and their inhibition has the potential to enhance the effectiveness of cancer treatments by inducing DNA damage in cancer cells, leading to cell death. Currently in preclinical development, ACR-2316 exemplifies Acrivon's strategy to leverage cutting-edge science to create more effective and precise cancer treatments.